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CObjective: To conduct a cost-effectiveness analysis of currently
available nucleos(t)ide antiviral treatments (lamivudine, telbivu-
dine, entecavir, and tenofovir) for chronic hepatitis B in Canada.
Methods: Markov modeling was used to project the lifetime health
benefits and costs associated with the antiviral treatments. The hypo-
thetical patient population was hepatitis B e antigen–positive chronic
hepatitis B–infected patients aged 34 years. Quality-adjusted life-years
were used as a measure of effectiveness. Long-term cumulative inci-
dence of liver complications was also projected. Treatment effective-
ness data were derived from the literature; meta-analysis was con-
ducted when there was a large variance in reported effectiveness data.
Costs were obtained from a cost analysis of treating chronic hepatitis
B–related complications in Canada. Stochastic parameter uncertainty
was examined in probabilistic sensitivity analysis by using second-
order Monte Carlo simulation. Alternativemodeling assumptions were
assessed in scenario analysis. One-way sensitivity analysiswas used to
explore each parameter’s impact on the uncertainty of the results. O
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al So
http://dx.doi.org/10.1016/j.jval.2012.06.005esults: In the base-case analysis, telbivudine was dominated by en-
ecavir and tenofovir. Tenofovir strictly dominated lamivudine, tel-
ivudine, and entecavir. Over the 72-year period of the model, the ex-
ected life expectancy (undiscounted) of lamivudine, telbivudine,
ntecavir, and tenofovirwas 35.71, 36.94, 37.65, and 37.99 years, respec-
ively. Tenofovir had the highest expected quality-adjusted life-years
t 11.86 (discounted) in all comparisons. Scenario and sensitivity anal-
ses proved the robustness of the base-case results. The projected 10-
ear cumulative incidence of cirrhosis and hepatocellular carcinoma
as 11.40% and 3.05%, respectively, for tenofovir, which is significantly
ower than that for lamivudine. Conclusion: Tenofovir generated the
est results compared with all other therapies under evaluation.
eywords: antiviral treatments, chronic hepatitis B, cost-effectiveness
nalysis, Markov modeling, probabilistic sensitivity analysis.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
In Canada, the estimated number of hepatitis B virus (HBV)-in-
fected individuals is 5.2% in immigrants, 0.7% to 0.9% in Canadian-
born individuals, and 4% in aboriginals [1,2]. The projected sero-
prevalence of HBV in Canada is close to 1.26% [2]; therefore, there
are approximately 430,000 Canadians infected with HBV. With
20% to 25%mortality rate among untreated cases [2], chronic hep-
atitis B (CHB) infection has severe long-term outcomes and re-
quires complex algorithms for management. The Ontario Burden
of Infectious Disease study [3] estimated that 346 deaths per year
in Ontario are directly attributable to chronic HBV infection, and
an increasing burden to the health system is expected because of
new cases of cirrhosis, liver failure, and hepatocellular carcinoma
(HCC). Although antiviral treatments for CHB do not provide a
complete cure except for rare cases [2], timely treatment can sig-
nificantly prevent the progression of liver damage from HBV by
slowing down or stopping the virus from reproducing. Oral nucle-
os(t)ide analogues (NAs) have become the preferred first-line
treatment for most genotypes of hepatitis B due to relatively few
Note: This study was done when the principal investigator wa
* Address correspondence to: Jing He, Primary Health Care Inform
Street, Suite 300, Toronto, ON, Canada M2P 2B7.
E-mail: mail.jinghe@gmail.com.
1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.adverse effects compared with those of interferons. During the
past 5 years, a new generation of NAs has become available.
Lamivudine (LAM) was the first oral agent to be approved for
the treatment of HBV infection in Canada, and until 2006 it was the
only NA available. Although it is no longer recommended by the
Canadian Consensus Guidelines as the first-line choice for
the treatment of high viral load CHB (HBV DNA  2 107 IU/mL)
because of its low genetic barrier to developing resistance [2], it is
still the most commonly prescribed NA in clinical practice in On-
tario. According to a national survey, in 2009 77% of treatment-
naive patients with public funding received LAM in Ontario [4]. In
contrast, the consensus guidelines recommended telbivudine
(LdT) for patients with both low and high viral load; however, the
use of LdT in Canada was rare (2% in 2007 and 1% in 2009), mainly
because of provincial reimbursement restrictions and nonsuperi-
ority of LdT over other agents [4].
Entecavir (ETV) was recommended by the consensus guide-
lines as a first-line therapy for all patients regardless of viral load.
It was considered themost potent agent available before tenofovir
disoproxil fumarate (TDF) was officially licensed for hepatitis B [2].
New evidence has suggested that both TDF and ETV are the most
liated to McMaster University.
Division, Canadian Institute for Health Information, 4110 Yonge
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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895V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 9 4 – 9 0 6effective therapies for CHB [5,6], and the recent update of the
American Association for the Study of Liver Diseases (AASLD)
practice guideline (2010) has recommended TDF or ETV as the
first-line oral antiviral medications for CHB. From 2007 to 2009,
clinical practice in Canada showed a 525% increase in TDF use and
211% increase in ETV [4].
To date, there has been no economic evaluation studying re-
cently available nucleos(t)ide antiviral treatments for CHB from a
Canadian perspective. Therefore, this study aimed to conduct an
economic evaluation of these agents in Canada, using LAM as the
reference.
Methods
Overview
A cost-effectiveness analysis was conducted to evaluate LdT, TDF,
and ETV compared with LAM. A Markov model was chosen as the
preferred structure for the analysis because of the chronic and
recursive nature of chronic infection of HBV, which requires long-
term follow-up to capture the relevant clinical and economic end
points. The outcome measures used in the model were life-years,
quality-adjusted life-years (QALYs), and costs associated with the
treatments and disease progression. The analysis took the per-
spective of Ontario Ministry of Health and Long Term Care; there-
fore, only direct medical costs associated with CHB infection were
considered. The time horizon of the model was the patients’ life-
time. Clinical and economic outcomes were discounted at an an-
nual rate of 5% [7], as this is the recommended rate by Canada’s
TA agency. Microsoft Office Excel 2007 was used to conduct the
nalysis.
Patient population and treatment regimens
A hypothetical cohort of 1000 adult patients with the following
baseline characteristics was chosen to go through the model:
● Hepatitis B e antigen (HBeAg)–positive chronic HBV infection
without other coinfections and complications
● 34 years of age
● 72% males
● Mean serumalanine transaminase (ALT) level ranging from100
to 200 IU/L
● Mean serum HBV DNA concentration ranging from 107 to 1010
copies/mL
No prior treatment with anti-HBV nucleos(t)ides.
The characteristics of this patient cohort were based on effi-
acy trials from which key disease transition probabilities were
erived. Themodel employed 72 yearly cycles, since 99.99% of the
atient cohort has died by that time on the basis of the Ontario life
able [8].
Treatment regimens included in the model were LAM (Epivir)
00 mg daily, LdT (Sebivo) 600mg daily, TDF (Viread) 300mg daily,
nd ETV (Baraclude) 0.5 mg daily, all administered orally. For pa-
ients who developed viral resistance to their initial treatments,
hemodel employed rescue combination therapies recommended
y the Canadian and AASLD guidelines, because they are consis-
ent with the most effective care. In the case of LAM resistance,
defovir (ADV) (Hepsera, 10 mg) or TDF was added; the same
dd-on therapies were also used for LdT-resistant patients; for
atients resistant to TDF, LAMwas added; for ETV resistance, ADV
as used as the add-on therapy [2,4,9].
Markov model
Chronic infection with HBV can transition through multiple path-
ways. The diagram of disease transition under treatment is pre-sented in Figure 1. The patient cohort enters themodel in the CHB
state. While receiving antiviral therapies, patients could experi-
ence serum HBeAg seroconversion (i.e., the loss of HBeAg and the
gain of anti-HBe), representing that progressive liver damage has
been largely controlled but that they remain at risk of cirrhosis and
HCC [10-15]. Hepatitis B surface antigen (HBsAg) clearance could
also occur, indicating a cure of CHB. It is possible to develop viral
resistance on long-term nucleos(t)ide treatment. Rescue therapies
were administered to patients entering the resistance state. All
patients except those who have lost HBsAg remain at the risk of
developing cirrhosis and HCC over the long term. However, for
patients who did not seroconvert but achieved viral suppression,
the risk of developing cirrhosis and HCC may be reduced. During
severe disease stages including decompensated cirrhosis and
HCC, a liver transplant may be indicated. All states could lead to
death. BecauseMarkovmodels cannot holdmemory of the disease
transitionhistory, several temporary states (not all shown in Fig. 1)
were built to enable the assignment of state-specific transition
probabilities and to adjust utilities and costs.
Key modeling assumptions
1. International guidelines on the therapy of hepatitis B suggest
that finite duration of treatment with NAs is a reasonable op-
tion and recommend that treatment may be stopped after
HBeAg seroconversion and an additional 6 to 12months of con-
solidation therapy to maximize the durability of treatment re-
sponse [2,9]. Themodel employed the recommended treatment
strategy and 12-month consolidation therapy after the con-
firmed appearance of anti-HBe.
2. It was assumed that 60% of LAM-resistant and LdT-resistant
patients receive ADV add-on and that 40% of these patients
receive TDF add-on, according to the ratio of patients receiving
these rescue therapies in clinical practice in Canada [2,4,9]. We
did not consider alternative therapies that accounted for less
than 10% in Canadian clinical practice and that were not rec-
ommended by international guidelines.
3. Hundred percent durability of HBeAg seroconversion was as-
sumed during consolidation therapy. When off treatment, se-
rologic durability varied across antivirals. In the case of sero-
logic relapse, whichmeans HBeAg seroconversion reverses and
is considered a reactivation of hepatitis B [2], reinstitution of the
initial antiviral treatment was applied to patients who had not
Chronic 
hepas B 
Compensated 
cirrhosis 
Hepatocellular 
carcinoma 
Liver 
transplant 
HBeAg sero-
conversion 
Decompensated 
cirrhosis 
Post LT 
HBsAg 
clearance 
Drug 
resistance 
Fig. 1 – Health state transition diagram for the Markov
model. HbeAg, hepatitis B e antigen; HbsAg, hepatitis B
surface antigen; LT, liver transplant.developed viral resistance [9].
896 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 9 4 – 9 0 6Table 1 – Treatment-induced transition probabilities and relative risks.
Variable Deterministic Lower
value
Upper
value
Distribution Alpha/mean
of ln(RR)
Beta/SE of
ln(RR)
Reference
1 prob CHB to HBeAg
seroconversion
yr1_LAM
0.1800 0.1500 0.2100 Beta 113.224032 515.798368 [5]
2 prob CHB to HBeAg
seroconversion
yr1_LdT
0.2100 0.1400 0.3200 Beta 10.85095061 40.82024278 [5]
3 prob CHB to HBeAg
seroconversion
yr1_TDF
0.2000 0.0700 0.4300 Beta 2.12384121 8.495364839 [5]
4 prob CHB to HBeAg
seroconversion
yr1_ETV
0.1900 0.1000 0.2700 Beta 17.36191025 74.01656475 [5]
5 prob CHB to HBeAg
seroconversion
yr1_ADV
0.1700 0.0800 0.3000 Beta 5.28257155 25.79137875 [5,21]
6 prob CHB to HBeAg
seroconversion yr2
0.1200 0.0701 0.1699 Beta 20 144 [22]
7 prob resistance yr1_LAM 0.1173 0.0917 0.1429 Beta 71.108 535.130 [23,24]
8 prob resistance
yr2_LAM
0.2200 0.2023 0.2376 Beta 465.3260944 1649.792517 [6]
9 relative risk of resistance
yr1_LdT
0.4700 0.3200 0.7200 Lognormal 0.755022584 0.206869953 [23,24]
10 relative risk of resistance
yr2_LdT
0.4700 0.3200 0.7200 Lognormal 0.755022584 0.206869953 Assumed equal
to year 1
11 prob resistance_TDF 0.0030 0.0000 0.0072 Beta 2 661 [25]
12 prob resistance_ETV 0.0030 0.0000 0.0072 Beta 2 661 [25]
13 prob serologic relapse_off
treatment_LAM
0.1785 0.1477 0.2092 Beta 106.1016862 488.4493117 [22,26–31]
14 prob serologic relapse_off
treatment_LdT
0.1433 0.0926 0.1939 Beta 26.22786491 156.8601389 Adjusted based
on [22,28,30]
15 prob serologic relapse_off
treatment_TDF
0.1300 0.0790 0.1810 Beta 21.62 144.6876923 Assumed equal
to ETV
durability
16 prob serologic relapse_off
treatment_ETV
0.1300 0.0518 0.2082 Beta 9.1 60.9 Adjusted based
on [22,28,30]
17 prob CHB to Cirrhosis
yr1_LAM
0.0200 0.0055 0.0345 Beta 7.1 347.9 Adjusted based
on [32,33]
18 prob CHB to Cirrhosis
yr1_LdT
0.0090 0.0004 0.0176 Beta 4.122 453.878 Adjusted based
on [5,34,32]
19 prob CHB to Cirrhosis
yr1_TDF
0.0055 0.0000 0.0169 Beta 0.88 159.12 Adjusted based
on [5,21,32]
20 prob CHB to Cirrhosis
yr1_ETV
0.0070 0.0000 0.0157 Beta 2.478 351.522 Adjusted based
on [5,32,33]
21 prob CHB to Cirrhosis
yr1_ADV
0.0300 0.0000 0.0663 Beta 2.52 81.48 Adjusted based
on [5,21,32]
22 relative risk CHB to HCC
yr1_LAM
0.5246 0.3190 0.7302 Lognormal 0.645137961 0.211306622 [34]
23 relative risk CHB to HCC
yr1_LdT
0.2092 0.1272 0.2912 Lognormal 1.564417506 0.211306622 [35]
24 relative risk CHB to HCC
yr1_TDF
0.1283 0.0780 0.1786 Lognormal 2.053537499 0.211306622 [35]
25 relative risk CHB to HCC
yr1_ETV
0.1521 0.0925 0.2117 Lognormal 1.883412919 0.211306622 [35]
26 relative risk CHB to HCC
yr1_ADV
0.5246 0.3190 0.7302 Lognormal 0.645137961 0.211306622 [35]
27 prob Resistance to HBeAg
seroconversion yr2
0.1200 0.0701 0.1699 Beta 19.406496 142.314304 Assumed equal
to add-on
therapy
28 proportion of LAM
resistance receiving
ADV
0.6000 0.3648 0.8352 Beta 9.4 6.266666667 [4]
29 proportion of LAM
resistance receiving
TDF
0.4000 0.2432 0.5568 Beta 14.6 21.9 [4](continued on next page)
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897V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 9 4 – 9 0 64. Because of relatively poor virologic durability reported in the
literature [16], reduction in cirrhosis and HCC risk for nonsero-
converters was therefore assumed to occur only in the first 5
years of antiviral treatment in the base-case analysis; in subse-
quent years, the risk of cirrhosis and HCC was the same as the
baseline.
5. Treatment effects of rescue therapies were assumed to be the
same as those of the add-on therapies, since no significant dif-
ference was found in the literature [17], except the resistance
rate, which was assumed to be zero under rescue therapies
[18,19].
6. After patients progressed to more severe disease states (cirrho-
sis, decompensated cirrhosis, andHCC), transition probabilities
and costs were associated with routine clinical practice in
Canada [20].
Data for treatment effectiveness
All treatment-induced transition probabilities employed in the
model are shown in Table 1. Important transition probabilities
include HBeAg seroconversion and its off-treatment durability,
HBsAg seroclearance, drug resistance, and the risks of cirrhosis
and hepatoma.
HBeAg seroconversion
Probability of HBeAg seroconversion was assumed to be higher in
the first year of treatment than in subsequent years. First year
on-treatment HBeAg seroconversion probabilities were derived
froma recently published Bayesianmeta-analysis byWoo et al. [5].
Starting from the second year, annual seronconversion rates were
basically the same regardless of the time on treatment or the NA
used [22]; therefore, the model used a constant seroconversion
robability (12%) that was equal across antivirals for the following
ears of treatment.
HBeAg seroconversion durability
Although some studies reported comparable off-treatment se-
rologic durability (70%–90%) across antivirals, differences com-
pared with LAM were reported in two head-to-head studies
[22,30]: 72% for LAM and 77% for ETV in Gish et al.’s study [22];
93% for LAM and 86% for LdT in Poynard et al.’s [30] study.
Table 1 (continued)
Variable Deterministic Lower
value
Uppe
valu
30 proportion of LdT
resistance receiving
ADV
0.6000 0.3648 0.835
31 proportion of LdT
resistance receiving
TDF
0.4000 0.2432 0.556
32 prob HBeAg
seroconversion to
HBsAg loss_LAM
Equal to baseline
33 prob HBeAg
seroconversion to
HBsAg loss_LdT
Equal to baseline
34 prob HBeAg
seroconversion to
HBsAg loss_TDF
0.1153 0.0848 0.145
35 prob HBeAg
seroconversion to
HBsAg loss_ETV
0.0811 0.0527 0.109
ETV, Entecavir; HbeAg, hepatitis B e antigen; HbsAg, hepatitis B surfac
dine; RR, relative risk; SE, standard error; TDF, tenofovir disoproxil fuOverall, limited data exist on the off-treatment durability of wHBeAg seroconversion achieved with newer NAs. We calculated
the weighted average (fixed-effect meta-analysis using inverse
variance method) of LAM’s durability data in four studies, and
adjusted the reported data of LdT and ETV to make them con-
sistent with the relative difference across antivirals. TDF’s du-
rability was assumed to be the same as that of ETV.
HBsAg seroclearance
Recent studies estimated that baseline HBsAg clearancewas 1% to
2% among asymptomatic HBsAg carriers (mostly seropositive for
anti-HBe) with a mean age of 33 years [37]. A fixed-effect meta-
analysis was conducted for studies that reported spontaneous
HBsAg loss during long-term follow-up and derived 0.9% transi-
tion probability [37,38]. Besides, studies showed that HBsAg clear-
ance under NA treatments is confined to those with an active
immune response to HBV, such as HBeAg-positive patients who
achieve HBeAg clearance [39]. Therefore, it was assumed that all
HBsAg seroclearance occurred in HBeAg seroconverters. Accord-
ing to the literature, NAs generally have a low rate of HBsAg loss
compared with interferon [40], and HBsAg clearance was not ob-
served in any patient treated with LAM and LdT [5]; therefore, we
used baseline probability for LAM and LdT. A systematic review
also indicated that sustained effects of antiviral treatments on
HBsAg loss beyond 48 weeks off treatment have not been exam-
ined [41]. We therefore assumed that all drug-induced HBsAg se-
roclearance occurred only in the first year after HBeAg seroconver-
sion; in subsequent years, HBsAg clearance rate was assumed to
be the same as baseline.
Drug resistance
First-year resistance probabilities in the model were based on a
meta-analysis conducted for this study and a published review
of clinical trials [23,42]. For each drug, cumulative long-term
esistance probabilities were converted to an annual probability
hat was applied to subsequent years of antiviral treatment.
esistance to ETV is rare (1% for 3 years of treatment) in clin-
cal trials [25], and no TDF resistance was observed in clinical
rials [21,43]. Longer-term follow-up, however, found that resis-
ance to TDF and ETV occurred eventually, and in most cases it
Distribution Alpha/mean
of ln(RR)
Beta/SE of
ln(RR)
Reference
Beta 9.4 6.266666667 [4]
Beta 14.6 21.9 [4]
Beta 48.67196304 373.5999747 Meta-analysis
of [21,36]
Beta 28.7027027 325.2972973 [33]
igen; HCC, hepatocellular carcinoma; LAM, lamivudine; LdT, telbivu-
te.r
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898 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 9 4 – 9 0 6therefore assumed that the annual resistance probability of ETV
and TDF was 0.3%.
Risk for cirrhosis
It was found that HBV viral load was the strongest predictor for
the development of cirrhosis, independent of serum ALT level
and HBeAg status [32]. According to Iloeje’s 11-year population-
based prospective cohort study, annual risks for cirrhosis are
0.42%, 0.55%, 0.93%, and 2.41% for serum HBV DNA level less
than 300, 300 to 104, 104 to 105, and 105 to 106 copies/mL, respec-
ively. Transition probabilities from CHB to cirrhosis were then
alculated on the basis of mean HBV DNA levels at the end of 1
ear of therapy. The probabilities were adjusted slightly to ac-
ount for the difference in baseline HBV DNA levels across ran-
omized controlled trials and different drugs’ potency on viral
uppression [5,21,24,33].
Risk for HCC
Because HBV is an oncogenic virus, it can cause HCC in the
absence of cirrhosis [45]. In HBV carriers without cirrhosis, the
risk is 0.02% to 0.03% per year in Caucasians and 0.4% to 0.6% in
Asians [46]. Given that chronic HBV carriers in Ontario are
Table 2 – Other transition probabilities.
Variable Deterministic Lower value Uppe
1 prob HBeAg
seroconversion to
HBsAg loss
0.0080 0.0043 0
2 prob HBeAg
seroconversion to
Cirrhosis
0.0006 0.0000 0
3 prob HBeAg
seroconversion to HCC
0.0003 0.0000 0
4 prob CHB to Cirrhosis 0.0400 0.0336 0
5 prob CHB to HCC 0.0061 0.0000 0
6 prob Resistance to
Cirrhosis
0.0400 0.0243 0
7 prob Resistance to HCC 0.0053 0.0000 0
8 prob Cirrhosis to
Decompensated
cirrhosis
0.0343 0.0063 0
9 prob Cirrhosis to HCC 0.0410 0.0092 0
10 prob Decompensated
cirrhosis to HCC
0.0655 0.0199 0
11 prob Decompensated
cirrhosis to Liver
transplant
0.2286 0.0914 0
12 prob HCC to Liver
transplant
0.3519 0.2806 0
13 prob CHB to Death Equal to all cause mortality (life ta
14 prob Resistance to Death Equal to all cause mortality (life ta
15 prob HBeAg
seroconversion to
Death
Equal to all cause mortality (life ta
16 prob HBsAg clearance to
Death
Equal to all cause mortality (life ta
17 prob Cirrhosis to Death 0.0233 0.0082 0
18 prob Decompensated
cirrhosis to Death
0.2094 0.0499 0
19 prob HCC to Death 0.2681 0.1192 0
20 prob Liver transplant to
Death
0.1260 0.1103 0
21 prob Post liver transplant
to Death
0.0482 0.0381 0
CHB, chronic hepatitis B; HbeAg, hepatitis B e antigen; HbsAg, hepatimostly immigrant populations, we used baseline HCC risk datafrom a Korean study without adjustments. Currently estab-
lished major risk factors for HCC in patients with CHB include
sex, age, serum ALT concentration, HBeAg status, and serum
HBV DNA level [35]. Eun et al. [34] reported that HBV DNA levels
greater than 104 copies/mL is an especially strong predictor of
CC risk in individuals aged 30 years or older. The quantitative
elationship between on-treatment HBV viral load and the risk
f developing HCC, however, is not yet well established, and
tudies regarding HCC risk are limited to conventional inter-
eron and LAM [47]. We calculated HCC risk on the basis of Yang
t al’s study [35] of a risk scoring system that takes into account
he above stated risk factors, and randomized controlled trials
5,21,24,33] that reported HBV DNA concentration at the end of
-year therapy.
Other transition probabilities
Please refer to Table 2 for all other transition probabilities used in
the model. When assumptions were made on the range of param-
eter values, standard errors were assumed to be 20% of point es-
timates. The Canadian life table (2002 Ontario) was used for back-
lue Distribution Alpha Beta Reference
Beta 17.56346364 2187.148529 Meta-analysis of
[37,38,48,49]
Beta 0.111760917 183.8882391 [38]
Beta 0.0567 188.9433 [38]
Beta 143.28 3438.72 [32]
Beta 2.6779 436.3221 [34]
Beta 23.96 575.04 Assumed equal
to CHB2C
Beta 0.8321 156.1679 [34]
Beta 5.517421876 155.4825781 [50]
Beta 6.068 141.932 [34]
Beta 7.336 104.664 [34]
Beta 8 27 [51]
Beta 60.17933406 110.8206659 [52]
[8]
[8]
[8]
[8]
Beta 8.945886122 375.0541139 [8,53]
Beta 5.026334039 18.97366596 [8,54]
Beta 8.848582314 24.15141769 [8,55]
Beta 217.098 1505.902 [8,56]
Beta 82.61434147 1630.385659 [8,57]
surface antigen; HCC, hepatocellular carcinoma.r va
.0117
.0042
.0028
.0464
.0134
.0557
.0166
.0623
.0728
.1111
.3657
.4233
ble)
ble)
ble)
ble)
.0384
.3689
.4170
.1417
.0584ground mortality [8].
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In Ontario, LAM, ETV, TDF, and ADV are reimbursed under the
Exceptional Access Program, in which the reimbursement rates
are the drug benefit price if they are listed in the Ontario Drug
Benefit Fomulary; otherwise, reimbursement rates are the
wholesale acquisition costs of the drugs. In this analysis, when
available, prices listed in Quebec’s formulary [58] were used as
the acquisition costs. Since LdT was not listed in either Quebec
or Ontario, the wholesale acquisition cost was obtained from a
local pharmacy [59]. An 8% pharmacy mark-up charge [60] and a
ispensing fee of Can $4.11 (i.e., Ontario Drug Benefit program
ee of Can $6.11 less a Can $2 patient co-payment) were used.
ost estimates for physician fees, test fees, procedure costs, and
ospitalization were taken from a cost analysis of treating CHB-
elated health conditions in Canada [20]. The costs associated
ith laboratory tests of creatinine and phosphate were included
or all the treatments under evaluation. Annual direct medical
Table 4 – Health-related quality of life data.
Variable Deterministic Lower value Upp
HBsAg clearance 0.9 0.85
HBeAg seroconversion 0.8 0.75
CHB 0.68 0.66
Resistance 0.68 0.66
Cirrhosis 0.69 0.66
Decompensated
cirrhosis
0.35 0.32
HCC 0.38 0.36
Liver transplant 0.57 0.54
Post–liver transplant 0.67 0.64
Table 3 – Daily drug costs and annual costs of health state
Variable Deterministic Lower
value
Upp
valu
Lamivudine (100 mg) 4.56 2.77
Telbivudine (600 mg) 18.30 11.12 2
Tenofovir (300 mg) 16.74 10.18 2
Entecavir (0.5 mg) 22.00 13.38 3
Adefovir (10 mg) 22.62 13.75 3
CHB 2623.00 2390.75 305
HBsAg clearance 83.01 62.25 10
HBeAg seroconversion 600.50 450.05 75
Drug resistance 2623.00 2390.75 305
Cirrhosis 3575.94 2860.04 534
Decompensated
cirrhosis
13441.81 9947.28 1961
Hepatocellular
carcinoma
15982.20 12699.57 2057
Liver transplantation 118598.73 112926.54 12789
Post–liver
transplantation
45782.13 40036.92 5517
US $ to Can $ exchange
rate (2008):
1.1962 Source: [62]
Can HC CPI* (2011 vs.
2001):
1.197168857 Source: Statistics Ca
Can HC CPI* (2011 vs.
2008):
1.084249084 Source: Statistics Ca
CHB, chronic hepatitis B; HbeAg, hepatitis B e antigen; HbsAg, hepati
* Consumer price index, health care, Canada.CHB, chronic hepatitis B; HbeAg, hepatitis B e antigen; HbsAg, hepatitis Bcosts (2001) for managing these CHB-related disease states were
as follows:
● CHB: Can $2,191 (antiviral drug costs not included)
● Compensated cirrhosis: Can $2,987
● Decompensated cirrhosis: Can $11,228
● HCC: Can $13,350
● Liver transplant (first year): Can $99,066
● Transplant care (subsequent years): Can $38,242
Please refer to Table 3 for drug costs and annual costs of health
states. The consumer price index (health care) was used to adjust
the costs to 2011 values [63].
Health utilities
Health-related quality of life (HRQOL) scores were obtained from
the study conducted by Levy et al. [65], in which trained interview-
lue Distribution Alpha Beta Source
Beta 123.5678 13.7298 Assumption
Beta 195.8899 48.9725 Assumption
Beta 1420.4047 668.4257 [65]
Beta 1420.4047 668.4257 Assumed equal
to CHB
Beta 1416.7740 636.5216 [65]
Beta 764.3685 1419.5415 [65]
Beta 381.7653 622.8802 [65]
Beta 595.7616 449.4342 [65]
Beta 1422.0377 700.4067 [65]
11 values, Can $).
Distribution Alpha Beta Source
Gamma 25 0.182332 [58]
Gamma 25 0.731857143 [59]
Gamma 25 0.669504 [60]
Gamma 25 0.88 [58]
Gamma 25 0.904908 [58]
Gamma 236.0659088 11.11129083 [61]
Gamma 65.49508262 1.267372098 [61]
Gamma 61.20094756 9.811958594 [20]
Gamma 236.0659088 11.11129083 Assumed equal
to CHB
Gamma 31.90391467 112.0847838 [20]
Gamma 29.67985164 452.8935014 [20]
Gamma 63.27248516 252.593275 [20]
Gamma 964.3928847 122.9776079 [20]
Gamma 140.5673165 325.6954218 [20]
[63]
[64]
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900 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 9 4 – 9 0 6ers were used to elicit utilities of CHB-related health states from
534 infected respondents by using the standard gamble technique.
Data were collected from respondents enrolled internationally.
Relevant dimensions of HRQOL were based on the Liver Disease
Quality-of-Life Instrument version 1.0, and the final version of
health state descriptions achieved consensual agreement among
experts. Please refer to Table 4 for HRQOL data (age and sex ad-
usted) associated with each health state.
Analysis of uncertainty
Probabilistic sensitivity analysis
In addition to using point estimates for input values, our disease
transition model was made probabilistic to assess the simulta-
neous impact of parameter uncertainty on the analysis. The
probability distribution for each input parameter is presented in
Tables 1 to 4. Beta distributions were assumed for probability
nd utility values; Gamma distributions were used for cost vari-
bles; lognormal distributions were assumed for relative risk
ariables. Second-order Monte Carlo simulation was conducted
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Fig. 2 – Base-case analysis results (ICERs) of all treatment alt
Table 5 – Base-case cost and effectiveness results of treatm
Lamivudine
Cost (undiscounted) $111,300 ($297,558) $
QALYs (undiscounted) 11.11 (25.97)
Life-years (undiscounted) 15.35 (35.71)
Incremental cost* —
Incremental life-years* —
Incremental QALYs* —
Incremental cost effectiveness
($/QALY)*
—
10-year cumulative incidence
of liver complications
Cirrhosis 17.23%
Decompensated cirrhosis 2.07%
Hepatocellular carcinoma 5.20%
Note. All costs are expressed in 2011 Canadian dollars (Can $).
QALY, quality-adjusted life-years.
* Discounted values.
† Dominated by entecavir and tenofovir.
‡ Dominated by tenofovir.
§ Dominates lamivudine, telbivudine, and entecavir.effectiveness plane. ICERs, incremental cost-effectiveness ratios;by using 2000 trials for the probabilistic analysis. Uncertainty in
the results was expressed by using cost-effectiveness accept-
ability curves based on the net benefit framework [66]. Willing-
ness-to-pay (WTP) per QALY gained ranged from $0 to $200,000.
Scenario analysis of alternative model assumptions
Two scenarios were considered for parameters that are not ad-
equately studied so far. Scenario 1 was to assume equal sero-
logic durability (82%) across antivirals after 12 months of con-
solidation therapy. Scenario 2 was to assume reduced risk of
developing cirrhosis and HCC sustained until the termination of
antiviral therapy.
One-way sensitivity analysis
The impact of parameter uncertainty for the optimal strategy
was also explored in one-way sensitivity analysis on each pa-
rameter. The analysis was based on the net monetary benefit
framework and was focused on the optimal strategy (i.e., TDF)
in the deterministic model. Despite the lack of an explicit WTP
1.00  2.00  
Incremental QALYs 
cavir 
 $19930/QALY 
Tenofovir 
tives compared with lamivudine shown on cost-
alternatives.
bivudine Entecavir Tenofovir
66 ($344,051) $123,575 ($301,545) $104,034 ($259,754)
45 (27.13) 11.57 (26.32) 11.86 (28.82)
68 (36.94) 15.82 (37.65) 15.90 (37.99)
$25067 $12275 $7266
0.33 0.47 0.55
0.34 0.62 0.75
minated† Dominated‡ Dominant§
13.41% 12.05% 11.40%
1.37% 1.11% 1.00%
3.72% 3.26% 3.05%Ente
ICER
ernaent
Tel
136,3
11.
15.
DoQALY, quality-adjusted life-year.
901V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 9 4 – 9 0 6threshold in Canada, most Canadian cost-effectiveness studies
quote Can $50,000 to Can $100,000 per QALY as the threshold.
The threshold is an unknown variable, as this depends on deci-
sion makers and societal willingness to pay for outcomes. For
illustrative purposes, in our analysis, we used WTP Can $50,000
per QALY to calculate the net monetary benefits.
440,000 450,000 460,000
Prob. seroconversion (yr2+) 
TDF cost 
Prob. TDF relapse 
Prob. TDF seroconversion (yr1) 
Prob. CHB to HCC 
Ulity_seroconversion 
Prob. cirrhosis to decompensated cirrhosis 
Prob. ETV relapse 
Prob. TDF HBsAg clearance 
Prob. CHB to cirrhosis 
Fig. 3 – One-way sensitivity analysis results of the optimal s
(presented on net monetary benefits scale*). CHB, chronic he
HCC, hepatocellular carcinoma; QALY, quality-adjusted life-
pay threshold of $50,000 per QALY.
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Model validation and calibration
Themodelwasvalidated inseveraldifferentways. First, a replicateof
the model was built by using TreeAge Pro software (TreeAge Soft-
00 480,000 490,000 500,000 510,000 520,000 
482,382 (baseline) 
0.07-0.17 
10.18-23.3 
0.08-0.18 
 
0.07-0.43 
0 - 0.134 
0.75-0.85 
0.0063-0.0623 
0.0848-0.1457 
0.0336-0.0464 
0.85-0.95 
gy (tenofovir) for the 10 most influential parameters
tis B; ETV, entecavir; HbsAg, hepatitis B surface antigen;
; TDF, tenofovir disoproxil fumarate. *Using willingness-to-
00 $120 $140 $160 $180 $200 
Value of WTP threshold (in thousands) 
dine Tenofovir Entecavir  470,0
trate
pati
year$1
lbivubase-case scenario. WTP, willingness to pay.
902 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 9 4 – 9 0 6ware, Inc., 2011 version); the same results were generated. Second,
the 10-year cumulative incidence of liver complications and undis-
counted life expectancy projected by the model was compared with
those from other published economic evaluations (see Discussion
section). Third, the risk of HCC was compared with the original
source of the HCC risk assessment under long-term LAM treatment
[34]: a 4-year cumulative HCC incidence was 1.46% in themodel and
1.53% (median 4.4 years) in the observational study.
Base-case analysis
Table 5 shows the results of each therapy byusing point estimates as
the model inputs. Discounting had a substantial impact on the cal-
culation of expected values; therefore, both discounted and undis-
counted health and monetary benefits were presented. Over the
72-year period of the model, the expected life expectancy (undis-
counted) under LAM, LdT, ETV, and TDF treatmentswas 35.71, 36.94,
37.65, and 37.99 years, respectively. LdT had the highest expected
cost (discounted) of Can $136,366 and the highest incremental cost
per QALY gained compared with LAM. TDF had the lowest expected
cost (discounted) of Can $104,034— it actually generated Can $7266
cost savings compared with the reference therapy over the patient
cohort’s lifetime. TDF also had the highest expected QALYs of 11.86
(discounted) over a lifetime, with 0.75 incremental QALYs compared
with LAM. We can also see from the cost-effectiveness plane (Fig. 2)
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Fig. 5 – Incremental cost-effectiveness comparisons for selec
and QALY results of 2000 simulations. QALY, quality-adjustthat on average, TDF generated the best results. It dominated bothLdT and ETV with lower cost and better effectiveness. The 10-year
cumulative incidence of cirrhosis, decompensated cirrhosis, and
HCCunderLAMtreatmentprojectedby themodelwas17.23%,2.07%,
and 5.20%, respectively, while under TDF treatment, the risks were
significantly lower: 11.40%, 1%, and 3.05%, respectively.
One-way sensitivity analysis
One-way sensitivity analyses for TDF were conducted by varying all
model parameters over their range of values. The 10most influential
parameters were selected for the Tornado diagram (Fig. 3). The key
drivers on the uncertainty of the results were found to be HBeAg
seroconversion rates in the first and subsequent years under TDF,
the cost of the drug, and its relapse rate. However, none of these
variations changed the status of TDF being the most cost-effective
treatment, except ETV’s relapse rate. By using threshold analysis,we
found that when ETV’s probability of relapse is below 0.074, ETV is
preferred over TDF as the optimal treatment strategy.
Probabilistic sensitivity analysis
The uncertainty of the cost-effectiveness results for a range of
WTP thresholds is presented as cost-effectiveness acceptability
curves in Figure 4. The cost-effectiveness acceptability curves
for the base-case scenario showed that TDF was the most cost-
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treatments. The scatter plots show the difference in cost
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903V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 9 4 – 9 0 6thresholds less than Can $200,000, followed by ETV, which was
the optimal strategy in 11% to 27% of the simulations. For ceiling
ratios (maximum WTP per QALY) beyond Can $200,000, the
probability of being the most cost-effective strategy stayed
steady for all comparators. LdT was almost never the most cost-
effective treatment regardless of how high the ceiling ratio was
set. At thresholds below Can $40,000, LAM was the optimal
strategy in as much as 23.7% of the simulations.
Scatter plots provided more detailed information in individ-
ual comparisons. It was indicated that in the base-case sce-
nario, TDF dominated LAM, LdT, and ETV in 71%, 91%, and 56%
of the simulations, respectively (Fig. 5A–C); ETV dominated LAM
in about 28% of the simulations, and in most other cases was
more costly and more effective than LAM (Fig. 5D). The proba-
bility of ETV’s incremental cost-effectiveness ratio (ICER) (com-
pared with that of LAM) being below Can $20,000 per QALY was
54% while that of TDF was 90%.
Scenario analysis
When setting the HBeAg serologic durability rate to be the same as
reference therapy and equal across antivirals, ICERs of the treat-
ments increased. TDF still generated cost savings and dominated all
other treatments. LdT was still the most costly and least effective
therapy comparedwithETVandTDF.Whenassuminga reduced risk
of cirrhosis andHCCsustaineduntil the terminationof antiviral ther-
apy, results were significantly improved: TDF’s QALYs increased
from 11.86 to 12.72 and cost decreased from Can $104,034 to Can
$93,564. ICERs were lower for all therapies (Table 6).
Discussion
This study is the first Canadian economic evaluation to assess the
cost-effectiveness of first-line oral NAs in the treatment of HBeAg-
positive CHB infections. The treatment regimens and associated
costs being modeled are based on clinical practice in Ontario. In
previously published decision-analytic models from other coun-
tries, some included ADV as an alternative strategy. This, how-
ever, was not considered in our study because its use is not com-
mon in Canada and it has beenmoved to second-line oral antiviral
medication according to the most recent AASLD guideline. We
therefore included ADV only as a rescue therapy for certain resis-
tance patients. Also, we used a more systematic way to identify
the clinical trials and conducted meta-analyses to derive the pa-
rameter inputs rather than relying on one single trial. Although
the differences in time horizon, perspective, discount rate, patient
population, modeling assumptions, and treatment regimen make
the comparison of cost and effectiveness estimates over time dif-
ficult, the life expectancy predicted by the model corresponded
closely to other published evaluations when using the same dis-
count rate. We were also able to compare the projected 10-year
cumulative incidence of cirrhosis and HCC with the results from
two other published economic evaluations [61,67] that reported
this data. Figure 6 shows the comparisons. Spackman and Veen-
stra’s study [61] assumed a fixed 4-year antiviral treatment in the
model and a reduced risk of cirrhosis and HCC applied only for the
first year of treatment. Yuan et al.’s model [67] assumed only a
1-year treatment of ETV versus LAM. Overall, the projected cumu-
lative incidence is lower in the presentmodel since the treatments
were assumed to reduce the risk of cirrhosis and HCC for 5 years.
Despite the differences between studies, the cost-effectiveness re-
sults of our study are highly consistent with previously published
economic evaluations. For example, modeling studies from the
United Kingdom [6] and Spain [68] demonstrated that first-line use
of TDF is more effective and less costly than first-line use of ETV,
ADV, and LAM. Earlier studies also showed that ETV dominated
LdT when TDF was still not available in their local settings.T S S S N H * † ‡ §
904 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 8 9 4 – 9 0 6There are some limitations of this study. For chronic HBV in-
fection, the outcomes of most interest for policy decision making
are life-years and QALYs, while the measures in clinical trials are
surrogate outcomes obtained at short-term follow-up (mostly 1
year). To extrapolate clinical trial results, especially the risk of
cirrhosis and HCC, better prediction tools should be examined by
further research. So far, observational studies on the long-term
risk assessment for HCC and cirrhosis under newer NAs are not
available in the literature, and current risk prediction tools were
not developed for on-treatment risk assessments. In addition, be-
cause of the lack of long-term observational data, it is impossible
to further validate the model and calibrate model estimates
against empirical data. We hope that future research can provide
such information for CHB-related complications, especially cir-
rhosis, decompensated cirrhosis, and HCC. Furthermore, the use
of time-dependent transition probabilities may be explored in fu-
ture economic evaluations, since age has been demonstrated to
significantly affect the incidence of CHB-related complications. A
comparison of the use of constant probabilities versus time-de-
pendent probabilities in modeling examined by Sun and Faunce
[69] found that there was a 10% difference in mortality rates when
using different transition probabilities from HBeAg-positive CHB
to cirrhosis over 40 years. HRQOL data used in this analysis were
generally slightly lower than those used in previously published
economic evaluations. This explains why the expected QALYs
were slightly lower than in other studies. A potential concern is
that the utility of CHB from Levy et al.’s study is lower than that of
compensated cirrhosis, which might have been influenced by the
descriptions of the diseases presented to the interview respon-
dents. Other published CHB-related health utility studies also
have the same issue. Given the results of our extensive sensitivity
analyses, however, we do not think that this affects the cost-ef-
fectiveness status of the treatment options. There are potential
concerns regarding the generalizability of the study results. We
suspect that the ICERs may vary by patient characteristics, be-
cause age, sex, baseline HBV DNA level, serum ALT level, family
history of cirrhosis, alcohol consumption, and smoking are all es-
tablished confounding factors of long-term CHB-related disease
progression. The chosen patient population in our model is based
on the clinical trials in which key disease transition probabilities
were derived. It could be that patients with certain risk factors or
coinfections may benefit more or less from the treatments under
evaluation, but this information is not available at this time.
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Fig. 6 – Comparison of 10-year cumulative cirrhosis (Whether any treatment option is clearly better on costs, utility, orboth is uncertain and that was the primary reason for conducting
the cost-utility model. Similarly, the cost-effectiveness and dom-
inance of any treatment in patient subgroups is uncertain due to
the lack of clinical effectiveness data in patient subgroups. Also,
this study focused on HBeAg-positive populations, because more
complex treatment regimens are used for HBeAg-negative pa-
tients, andmodifications to themodel structure and clinical effec-
tiveness data will be required. Future research is needed to eval-
uate the cost-effectiveness of NAs for certain patient subgroups
and HBeAg-negative CHB infections.
Conclusion
Results from the present analysis showed that for the specified
patient cohort with HBeAg-positive chronic HBV infection, antivi-
ral treatment with TDF appeared to be highly cost-effective and
the optimal strategy among NAmonotherapies. Probabilistic sen-
sitivity analysis demonstrated the robustness of the results.When
WTP thresholds range from 0 to Can $200,000 per QALY, there was
a 0.63 to 0.81 probability that TDF is the most cost-effective strat-
egy, followed by ETV, which had a 0.13 to 0.23 probability to be the
most cost-effective treatment. LAM was the optimal strategy for
lowerWTP thresholds (belowCan $40,000 per QALY) in asmuch as
23% of the simulations. In addition, TDF dominated all other alter-
native therapies in most simulations under different model as-
sumptions. The results are consistent with the AASLD guideline
that recommended that preference be given to ETV and TDF and
are also consistent with the current reimbursement conditions in
Ontario, which covers TDF without restrictions, along with LAM
and ETV in the Exceptional Access Program.
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